Short Lead Time for 2-Bromo-5-Chlorobenzaldehyde - Daptomycin 103060-53-3 for Infectious Diseases – Gentolex

Product Detail

Synonyms

N-[N-(1-Oxodecyl)-L-Trp-D-Asn-L-Asp-]-cyclo[L-Thr*-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-[(3R)-3-methyl-L-Glu-]-4-(2-aminophenyl)-4-oxo-L-Abu-];N-[N-Decanoyl-L-Trp-D-Asn-L-Asp-]-cyclo[Thr*-Gly-L-Orn-L-Asp-D-Ala-L-Asp-Gly-D-Ser-[(3R)-3-methyl-L-Glu-]-3-(2-aminobenzoyl)-L-Ala-];N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-threonylglycyl-L-ornithinyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-seryl-(3R)-3-methyl-L-α-glutamyl-α,2-diamino-γ-oxo-benzenebutanoicacid(13-4)lactone;DAPTOMYCINE;Dapcin;Daptomycin,>=99%;DaptomycinReadyMadeSolution;Daptomycin(LY146032)

Description

The antibiotic daptomycin is a cyclic lipopeptide antibiotic with a new structure extracted from the fermentation broth of Streptomyces (S. reseosporus), which hinders the biosynthesis of bacterial cell wall peptidoglycan by disturbing the transport of amino acids in the cell membrane. Altering the properties of the cytoplasmic membrane can disrupt bacterial membrane function in multiple ways and rapidly kill Gram-positive bacteria. In addition to its ability to act on most clinically relevant Gram-positive bacteria, daptomycin is more important for isolated strains that have shown resistance to methicillin, vancomycin, and linezolid in vitro. It has potent activity, and this property has very important clinical implications for critically ill infected patients. Eosinophilic pneumonia is a rare and very serious disease with symptoms including fever, cough, shortness of breath, and difficulty breathing.

Antibacterial Effect

Daptomycin has good bacteriostatic activity against various antibiotic-resistant bacteria, such as MIC=0.06-0.5 μg/ml for methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant Staphylococcus aureus (MRSA). MIC=0.0625～1μg/ml for bacteria, MIC=0.12～0.5μg/ml for oxacillin-resistant Staphylococcus epidermidis, MIC=2.5μg/ml for enterococcus highly resistant to aminoglycoside antibiotics, MIC=2.5μg/ml for GmrBIa -The MIC of Enterococcus is 0.5～1μg/ml, and the MIC of Enterococcus resistant to glycopeptide antibiotics is 1～2μg/ml.